Cambridge Investment Research Advisors, Inc. Nektar Therapeutics Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Nektar Therapeutics stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 132,180 shares of NKTR stock, worth $122,927. This represents 0.0% of its overall portfolio holdings.
Number of Shares
132,180
Previous 122,880
7.57%
Holding current value
$122,927
Previous $152,000
13.16%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding NKTR
# of Institutions
145Shares Held
139MCall Options Held
32.6KPut Options Held
14.1K-
Deep Track Capital, LP Greenwich, CT15.9MShares$14.8 Million0.76% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$14.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$12.2 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA9.4MShares$8.74 Million0.22% of portfolio
-
Samlyn Capital, LLC New York, NY9.2MShares$8.56 Million0.19% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $174M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...